Introduction to special issue

The Cancer Immunotherapy Revolution

See allHide authors and affiliations

Science  23 Mar 2018:
Vol. 359, Issue 6382, pp. 1344-1345
DOI: 10.1126/science.359.6382.1344

eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. eLetters are not edited, proofread, or indexed.  Please read our Terms of Service before submitting your own eLetter.

Compose eLetter

Plain text

  • Plain text
    No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

  • RE: The best cancer therapy is primary prevention
    • Sergio Stagnaro, Director, Quantum Biophysical Semeiotic Research Laboraory

    Despite of cancer immunotherapy has been pursued for more than a century, and rapid drug development, immediately approved from the U.S. Food and Drug Administration, cancer is today’s growing epidemic. The aim of immunotherapy is to manipulate components of the immune system and methods to genetically engineer patients' own T lymphocytes to recognize and attack their tumour, analogously to what happens physiologically by means of efficient cell information. Moreover, there is a general agreement on the statement the sooner it is better. But then, what accounts for the reason the Oncological Terrain-Dependent, Inherited Real Risk is so far overlooked by the great majority of physicians? Bedside diagnosed from birth, using a common stethoscope, such a predisposition to cancer is eliminated with inexpensive Reconstructing Mitochondrial Quantum Therapy, according to my clinical war against malignancy (1-).

    1) Stagnaro-Neri M., Stagnaro S. Introduzione alla Semeiotica Biofisica. Il Terreno Oncologico. Travel Factory, Roma, 2004.
    2) Sergio Stagnaro and Simone Caramel. BRCA-1 and BRCA-2 mutation bedside detection and breast cancer clinical primary prevention. Front. Genet. | doi: 10.3389/fgene.2013.00039.

    Show More
    Competing Interests: None declared.

Stay Connected to Science

Navigate This Article